Recent discussions on X about Iovance Biotherapeutics (IOVA) have been buzzing with activity following news of a competitor's setback. Posts on the platform highlight a significant stock price surge, with many pointing to the FDA's rejection of a rival melanoma therapy as a key driver, reducing near-term competition for Iovance’s own treatment. The conversation reflects a renewed focus on the company’s potential in the cell therapy space, with some users expressing optimism about upcoming regulatory approvals and earnings reports.
This spike in interest has also sparked debates over the sustainability of the rally, as some on X question whether the momentum can hold. There’s a palpable excitement among certain participants who see this as a pivotal moment for Iovance to solidify its market position. The dynamic nature of these discussions underscores the high stakes in the biotech sector, keeping the ticker in sharp focus.
Note: This discussion summary was generated from an AI condensation of post data.
Iovance Biotherapeutics Insider Trading Activity
Iovance Biotherapeutics insiders have traded $IOVA stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IOVA stock by insiders over the last 6 months:
- DANIEL GORDON KIRBY (Chief Commercial Officer) purchased 30,000 shares for an estimated $55,200
- RAJ K. PURI (Chief Regulatory Officer) purchased 5,600 shares for an estimated $9,743
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Iovance Biotherapeutics Hedge Fund Activity
We have seen 142 institutional investors add shares of Iovance Biotherapeutics stock to their portfolio, and 153 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC removed 9,400,478 shares (-42.5%) from their portfolio in Q1 2025, for an estimated $31,303,591
- INVENOMIC CAPITAL MANAGEMENT LP added 5,489,799 shares (+inf%) to their portfolio in Q1 2025, for an estimated $18,281,030
- LONG FOCUS CAPITAL MANAGEMENT, LLC added 4,118,055 shares (+80.2%) to their portfolio in Q1 2025, for an estimated $13,713,123
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,904,436 shares (-66.9%) from their portfolio in Q1 2025, for an estimated $13,001,771
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 3,869,617 shares (+202.8%) to their portfolio in Q1 2025, for an estimated $12,885,824
- RENAISSANCE TECHNOLOGIES LLC added 3,511,400 shares (+inf%) to their portfolio in Q1 2025, for an estimated $11,692,962
- AVORO CAPITAL ADVISORS LLC removed 3,500,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $11,655,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Iovance Biotherapeutics Analyst Ratings
Wall Street analysts have issued reports on $IOVA in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Chardan Capital issued a "Buy" rating on 07/23/2025
- Mizuho issued a "Outperform" rating on 05/12/2025
- Barclays issued a "Overweight" rating on 05/12/2025
- Goldman Sachs issued a "Buy" rating on 05/12/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/09/2025
- Truist Securities issued a "Buy" rating on 03/03/2025
- Baird issued a "Outperform" rating on 02/28/2025
To track analyst ratings and price targets for Iovance Biotherapeutics, check out Quiver Quantitative's $IOVA forecast page.
Iovance Biotherapeutics Price Targets
Multiple analysts have issued price targets for $IOVA recently. We have seen 9 analysts offer price targets for $IOVA in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $25.0 on 07/23/2025
- David Dai from UBS set a target price of $2.0 on 05/16/2025
- Andrea Tan from Goldman Sachs set a target price of $8.0 on 05/12/2025
- Mara Goldstein from Mizuho set a target price of $10.0 on 05/12/2025
- Peter Lawson from Barclays set a target price of $4.0 on 05/12/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $20.0 on 05/09/2025
- Asthika Goonewardene from Truist Securities set a target price of $15.0 on 03/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
